STOCK TITAN

PACS Group lifts 2026 revenue outlook to $5.95B–$6.05B

Full-year guidance now calls for $5.95 billion–$6.05 billion in revenue and $685 million–$695 million in Adjusted EBITDA.

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

PACS Group, Inc. (PACS) reported third-quarter 2026 revenue of $1.50 billion, up 11.5% year over year, and net income of $60.8 million, up 16.2%. Diluted EPS was $0.37 versus $0.32; Adjusted EPS was $0.63, up 37.0%. Adjusted EBITDA reached $175.7 million, up 33.6% from $131.5 million. Adjusted EPS and Adjusted EBITDA are non-GAAP measures.

PACS raised full-year 2026 guidance to $5.95 billion–$6.05 billion in revenue and $685 million–$695 million in Adjusted EBITDA, from prior ranges of $5.75 billion–$5.85 billion and $640 million–$660 million, respectively. The EBITDA guidance reflects approximately $5 million from retroactive Ohio quality incentive payments received in October. Subsidiaries closed on acquisitions of the operations of 11 Texas facilities—10 skilled nursing and one assisted living—as of November 1, 2026, and all 32 Florida facilities on October 1, 2026; collectively, the facilities comprise 4,049 skilled nursing beds. Cash provided by operating activities was $583.1 million for the nine months ended September 30, 2026.

4 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 Adjusted EBITDA guidance increased to $685 million–$695 million.
  • Moderate pointRevenue increased 11.5% to $1.50 billion year over year.
  • Moderate pointNet income rose 16.2% to $60.8 million year over year.
  • Moderate pointAdjusted EBITDA grew 33.6% to $175.7 million year over year.

Negative

  • None.

Filing Explained

At September 30, available liquidity was $707.4 million, including $115.3 million in cash and cash equivalents.

In its third-quarter report, PACS gives 158,723,071 common shares issued and outstanding at September 30, 2026, versus 156,615,144 at December 31, 2025, showing a higher reported common-share count at quarter-end.

PACS also reports $707.4 million of available liquidity at September 30, including $115.3 million of cash and cash equivalents, so the total is not all cash on hand.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Revenue $1.50 billion Third quarter 2026; up 11.5% year over year
Net income $60.8 million Third quarter 2026; up 16.2% year over year
Diluted EPS $0.37 per share Third quarter 2026; up 15.6% year over year
Adjusted EPS $0.63 per share Third quarter 2026; up 37.0% year over year
Adjusted EBITDA $175.7 million Third quarter 2026; up 33.6% from $131.5 million
Revenue guidance $5.95 billion–$6.05 billion Full-year 2026 guidance; raised from $5.75 billion–$5.85 billion
Adjusted EBITDA guidance $685 million–$695 million Full-year 2026 guidance; raised from $640 million–$660 million
Adjusted EBITDA financial
"Adjusted EBITDA is EBITDA further adjusted for non-core business items"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Adjusted EBITDAR financial
"Adjusted EBITDAR is a valuation measure"
Adjusted EBITDAR is a company’s reported profit measure that starts with operating earnings and then adds back interest, taxes, depreciation, amortization and rent, plus any one‑time items companies exclude. It aims to show how much cash a business generates from its core operations before the costs of financing, non‑cash accounting charges and property leases, like comparing two stores’ underlying sales by ignoring rent and loan payments. Investors use it to compare operating performance across firms and assess ability to cover fixed obligations, but companies may calculate it differently, so comparisons require caution.
skilled mix medical
"skilled mix increased to 29.1%"
Net Leverage financial
"Net Leverage is calculated as Net Debt divided by Last Twelve Months Adj. EBITDA"
Net leverage measures how many years it would take for a company to pay off its outstanding debt using its annual operating cash flow, after subtracting cash on hand from total debt. Think of it like a household’s mortgage balance minus savings divided by yearly income; a lower number means the company is in a safer position to handle debt, while a higher number signals greater financial risk and potential pressure on profits or growth.
Revenue $1.50 billion up 11.5% year over year
Net income $60.8 million up $8.5 million, or 16.2%, from the prior-year period
Diluted EPS $0.37 per share up 15.6% year over year
Adjusted Earnings Per Share $0.63 per share up 37.0% year over year
Adjusted EBITDA $175.7 million up $44.2 million, or 33.6%, from the prior-year period
Guidance

Full-year 2026 revenue guidance was raised to $5.95 billion–$6.05 billion from $5.75 billion–$5.85 billion; Adjusted EBITDA guidance was raised to $685 million–$695 million from $640 million–$660 million.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue and net income did PACS report in Q3 2026?

PACS reported $1.50 billion in revenue, up 11.5% year over year, and $60.8 million in net income, up $8.5 million, or 16.2%, from the prior-year period.

What is PACS's updated 2026 financial guidance?

PACS raised full-year 2026 revenue guidance to $5.95 billion–$6.05 billion and Adjusted EBITDA guidance to $685 million–$695 million. The prior ranges were $5.75 billion–$5.85 billion for revenue and $640 million–$660 million for Adjusted EBITDA; the midpoint of the new EBITDA range represents approximately 37% growth over 2025.

What facility operations did PACS acquire in Texas and Florida?

PACS subsidiaries closed on the operations of 11 Texas facilities—10 skilled nursing facilities and one assisted living facility—as of November 1, 2026, and all 32 Florida facilities on October 1, 2026. Collectively, the facilities comprise 4,049 skilled nursing beds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000200118400020011842026-11-032026-11-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 3, 2026
PACS GROUP, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4201192-3144268
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)
90 S. 400 W. Suite 700
Salt Lake City, Utah 84101
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (801) 447-9829
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.001 par value per sharePACSThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 2.02. Results of Operations and Financial Condition.
On November 3, 2026, PACS Group, Inc. (the “Company”) issued a press release announcing financial results for its third quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.Description
99.1
Press Release of the Company dated November 3, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PACS GROUP, INC.
Date: November 3, 2026
By:/s/ Carey Hendrickson
Carey Hendrickson
Chief Financial Officer




PACS Group, Inc. Reports Third Quarter 2026 Results

Conference Call and Webcast Scheduled for Tomorrow, November 4, 2026, at 11:30 am ET.

SALT LAKE CITY, Utah, November 3, 2026 – PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating results for the third quarter of 2026.
Third Quarter 2026 Financial Highlights

•Revenue was $1.50 billion, an increase of 11.5% over prior year.
•Net income was $60.8 million, an increase of $8.5 million, or 16.2% from $52.3 million in the prior-year period.
•Diluted Earnings Per Share was $0.37, an increase of 15.6% over prior year, and Adjusted Earnings Per Share was $0.63, an increase of 37.0% over prior year.1
•Adjusted EBITDA was $175.7 million, an increase of $44.2 million, or 33.6% from $131.5 million in the prior-year period.1
•Adjusted EBITDAR was $273.9 million.1

Third Quarter 2026 Select KPIs

•On a same-store basis, which includes the 284 skilled nursing facilities (“SNFs”) operated by the Company as of the beginning of 2025, SNF revenue increased 6.4% in the third quarter of 2026 compared to the prior-year period. Occupancy improved to 91.3% from 89.3% in the third quarter of 2025, and skilled mix increased in both revenue and nursing patient days.
•The Company had 250 facilities, or 78.9%, of its skilled nursing portfolio achieve a 4 or 5 star CMS Quality Measure Star rating, with its 196 mature facilities achieving an average rating of 4.5 as of September 30, 2026.
•Overall occupancy was 90.2%, compared to an industry average of 80.2%. Mature facilities occupancy was 93.1%.
•Mature facilities skilled mix was 31.3%, while overall skilled mix increased to 29.1%, an improvement of 90 basis points from 28.2% in the prior-year period, driven by continued improvement in our Ramping facilities cohort.
•Cash provided by operating activities was $583.1 million for the nine months ended September 30, 2026.
•The Company deployed $213.0 million in capital for M&A during the third quarter of 2026, bringing the total M&A investment to $403.8 million for the first nine months of the year.
•As of September 30, 2026, the Company had $707.4 million in available liquidity, including $115.3 million of cash and cash equivalents.

“Our third quarter results reflect the continued progress our teams are making across the organization, both in the quality of care we provide and the performance of our facilities,” said Jason Murray, PACS Chief Executive Officer. “Same-store revenue increased 6.4%, occupancy improved to 91.3%, and skilled mix continued to strengthen. Importantly, 78.9% of our skilled nursing facilities achieved four- or five-star CMS Quality Measure ratings, reflecting the dedication of our local teams and their commitment to delivering exceptional patient care.

“At the same time, we're entering an exciting period of growth for PACS. Our recent expansion into Florida and continued growth in Texas significantly broaden our geographic reach and create new opportunities to bring our operating model to more communities. As we continue to grow, our focus remains on empowering local leaders, improving clinical outcomes, and building strong operations that create lasting value for our patients, employees, and shareholders.”

“Our third quarter results demonstrate the increasing earnings power of the PACS operating model, with Adjusted EBITDA growth significantly outpacing revenue growth,” said Carey Hendrickson, PACS Chief Financial Officer. “Revenue increased 11.5% year-over-year to $1.50 billion, while Adjusted EBITDA grew 33.6% to $175.7 million. This performance
1 Adjusted Earnings Per Share, Adjusted EBITDA, and Adjusted EBITDAR are Non-GAAP Financial Measures. See “Reconciliation of GAAP to Non-GAAP Financial Information”.
1


reflects the continued progression of our facilities, disciplined operating execution, and our ability to translate revenue growth into stronger profitability.

“We also continue to generate substantial cash flow, with $583.1 million provided by operating activities through the first nine months of 2026. Combined with $707.4 million in available liquidity and net leverage2 of 0.2x at quarter-end, our financial position provides significant flexibility to support strategic acquisitions and real estate investments while maintaining a conservative capital structure. We believe this disciplined approach to capital allocation positions PACS to continue growing its operations and creating long-term shareholder value.”
Growth Highlights
Subsidiaries of PACS entered into a definitive agreement to acquire the operations of 10 skilled nursing facilities and one assisted living facility in Texas. As of November 1, 2026, PACS has closed on its acquisition of the operations of all 11 Texas facilities.

Additionally, as previously announced on September 1, 2026, subsidiaries of PACS entered into a definitive agreement to acquire the operations of 32 skilled nursing facilities across Florida, marking its entry into a new state. Collectively, the facilities comprise 4,049 skilled nursing beds. On October 1, 2026, PACS closed its acquisition of the operations of all 32 Florida facilities.

Revised 2026 Business Outlook

“Given the continued excellent performance of our portfolio across all cohorts, we are increasing our full-year 2026 Adjusted EBITDA guidance to a range of $685 million to $695 million, up from our prior range of $640 million to $660 million,” said Hendrickson. “At the midpoint, this represents approximately 37% growth over 2025.”

“We are also increasing our revenue guidance to $5.95 billion to $6.05 billion, up from our prior range of $5.75 billion to $5.85 billion."

“Our guidance reflects approximately $5 million of EBITDA contribution from retroactive quality incentive payments in Ohio received in the month of October. We also continue to see a robust pipeline of acquisition opportunities and remain actively engaged in evaluating transactions that meet our strategic, operational and financial criteria,” said Hendrickson.
As of today, PACS's growing portfolio comprises 398 healthcare operations across 21 states. PACS owns 66 facilities and leases an additional 49 facilities with partial ownership in real estate. PACS holds 37 purchase options on leased facilities and 20 purchase options through partnerships. The Company remains focused on acquiring underperforming and moderately performing operations where its operating model can drive meaningful improvement, while selectively investing in real estate to support long-term value creation.
A live webcast will be held November 4, 2026, at 11:30 a.m. Eastern time to discuss PACS’s third quarter financial results. To listen to the webcast please visit the Investor Relations section of PACS’s website at https://IR.pacs.com or by dialing 877-407-0621 / +1 215-268-9899. The webcast will be recorded and will be available for replay via the website for 30 days following the call.
About PACS™
PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate 398 post-acute care facilities across 21 states serving over 38,900 patients daily. References herein to the consolidated “Company,” as well as the use of the terms “we,” “us,” “our,” “its” and similar verbiage, refer to PACS Group, Inc. and its consolidated subsidiaries, taken as a whole. PACS Group, Inc. and its subsidiaries that are not licensed healthcare providers do not provide healthcare services to patients, residents or any other person, and do not direct or control the provision of services provided or the operations of those provider subsidiaries. All healthcare services are
2 Net Leverage is calculated as Net Debt divided by Last Twelve Months Adj. EBITDA. Net Debt is calculated as Long-Term Debt plus Outstanding Lines of Credit less Cash and Cash Equivalents.
2


provided solely by its applicable subsidiaries that are licensed healthcare providers, under the direction and control of licensed healthcare professionals in accordance with applicable law. More information about PACS is available at https://IR.pacs.com. The information on our website is not part of this press release.
Investors: IR@pacs.com

Media: Brooks Stevenson
VP Corporate Communication
90 S. 400 W. Suite 700
Salt Lake City, UT 84101
T: 385-988-3596
brooks.stevenson@pacs.com
https://www.pacs.com
https://ir.pacs.com
Forward Looking Statements Disclaimer
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact, including statements regarding our future financial performance and guidance, including expected revenue and adjusted EBITDA for fiscal year 2026, business strategy and growth plans, acquisition and integration activities, integration of our recently acquired Florida and Texas operations and related planned investments, operational and quality improvement initiatives, capital allocation and investment strategies, expectations regarding our acquisition pipeline and future transactions, uncertainty regarding the timing, amount, and continuation of payments under California's WQIP, Ohio's quality incentive program or similar state programs; our ability to execute share repurchases at favorable prices or at all, and the impact of repurchases on our capital position and liquidity; and other expectations, beliefs, plans, or objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” or “continue,” or the negative of these terms or other similar expressions. Forward-looking statements are neither promises nor guarantees and are based on management’s current expectations, estimates, forecasts and assumptions and on trends that we believe may affect our business, results of operations, financial condition and prospects. These statements are subject to risks, uncertainties and other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, our dependence on reimbursement from third-party payors, and changes in patient acuity mix, payor mix, payment methodologies, or new cost-containment initiatives could negatively impact our revenue and results of operations; we may not be fully reimbursed for all services billed through consolidated billing or bundled payments, reducing our revenue and financial condition; increased competition for, or shortages of, nurses, nurse assistants and other skilled personnel could raise labor costs and subject us to monetary fines; state efforts to regulate or deregulate healthcare services or the construction, expansion, or acquisition of healthcare facilities could impair our ability to expand or increase competition; failure to attract patients and residents or compete effectively with other healthcare providers may reduce our revenue and profitability; reviews and audits of care delivery, recordkeeping and billing may detect noncompliance requiring repayment of billed amounts or other costs; litigation and claims common in our industry could result in significant legal costs, settlements or damage awards, and our self-insurance programs may expose us to unexpected costs and losses; material weaknesses in our internal control over financial reporting, or failure to remediate such weaknesses or maintain effective controls, could impair timely and accurate reporting, reduce investor confidence, subject us to penalties, and affect the value of our common stock; inability to provide consistently high quality of care, or employee conduct that impacts patient health, safety or clinical treatment, could result in civil or criminal penalties and harm our operations; significant reliance on information technology, and any failure or interruption of that technology, could impair our operations; operational metrics derived from internal systems without independent verification may contain inaccuracies that harm our reputation; inability to complete acquisitions at attractive prices or at all may reduce revenue, and divestitures of underperforming or non-strategic subsidiaries would further decrease revenue; we may not successfully integrate acquired facilities, including our recently acquired operations in Florida, a state in which we have not previously operated, or achieve expected benefits; acquisitions may entail unforeseen costs, liabilities or regulatory issues that adversely affect our operations; difficulty completing partnerships consistent with our growth strategy; failure to achieve or maintain
3


competitive quality ratings from CMS or private rating organizations could negatively affect us; inability to obtain insurance or increases in insurance costs could impair our financial condition; geographic concentration of our facilities, including in California, increases vulnerability to local economic downturns, regulatory changes or natural disasters; actions of national labor unions may reduce our revenue and profitability; because we lease most facilities, we face risks from lease termination, extensions and special charges that could affect our financial condition and results of operations; insufficient cash flow to cover required payments or meet covenants under long-term debt, mortgages and leases could trigger defaults and cross-defaults, risking loss of facilities or foreclosures; we may need additional capital to fund operations and growth, which may be unavailable or available only on unfavorable terms; extensive and complex laws and regulations govern our industry, and noncompliance or regulatory changes could require significant expenditures or operational modifications; our founders, Jason Murray and Mark Hancock, hold substantial control and a substantial portion of our outstanding common stock, and their interests may conflict with those of other stockholders; as a "controlled company" under NYSE governance standards, we may rely on exemptions from certain requirements, and stockholders may not have the same protections afforded to stockholders of non-controlled companies. These and other important factors are described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings that we make with the Securities and Exchange Commission from time to time. Any forward-looking statements contained in this press release speak only as of the date hereof. We undertake no obligation to update any forward-looking statements contained herein to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
4


PACS GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(dollars in thousands, except for share and per share values)
Unaudited
September 30,December 31,
20262025
ASSETS
Current Assets:
Cash and cash equivalents$115,281 $197,016 
Accounts receivable, net660,256 628,128 
Other receivables89,847 73,965 
Prepaid expenses and other current assets81,356 170,630 
Total Current Assets946,740 1,069,739 
Property and equipment, net1,451,640 1,201,096 
Operating lease right-of-use assets2,969,730 2,968,176 
Insurance subsidiary deposits and investments164,703 87,192 
Escrow funds25,468 18,404 
Goodwill and other indefinite-lived assets151,115 68,061 
Other assets208,787 171,366 
Total Assets$5,918,183 $5,584,034 
LIABILITIES AND EQUITY
Current Liabilities:
Accounts payable$177,273 $192,232 
Accrued payroll and benefits252,885 187,516 
Current operating lease liabilities174,884 153,066 
Current maturities of long-term debt7,984 4,463 
Current portion of accrued self-insurance liabilities160,724 128,994 
Refund liability181,129 181,129 
Other accrued expenses227,423 154,030 
Total Current Liabilities1,182,302 1,001,430 
Long-term operating lease liabilities2,933,068 2,939,854 
Line of credit— 100,000 
Long-term debt, less current maturities, net of deferred financing fees264,350 244,803 
Accrued self-insurance liabilities, less current portion243,582 192,561 
Other liabilities76,169 152,937 
Total Liabilities$4,699,471 $4,631,585 
Commitments and contingencies
Equity:
PACS Group, Inc. stockholders' equity:
Common stock: $0.001 par value; 1,250,000,000 shares authorized; 158,723,071 shares issued and outstanding as of September 30, 2026, and 156,615,144 shares issued and outstanding as of December 31, 2025
159 157 
Additional paid-in capital686,635 637,035 
Retained earnings527,462 309,579 
Total PACS Group, Inc. stockholders' equity1,214,256 946,771 
Noncontrolling interest in subsidiary4,456 5,678 
Total Equity$1,218,712 $952,449 
Total Liabilities and Equity$5,918,183 $5,584,034 
5


PACS GROUP, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(dollars in thousands, except for share and per share values)
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenue
Patient and resident service revenue$1,498,137 $1,344,302 $4,345,593 $3,930,168 
Other revenues441 265 1,477 785 
Total Revenue $1,498,578 $1,344,567 $4,347,070 $3,930,953 
Operating Expenses
Cost of services1,142,144 1,046,262 3,306,218 3,090,932 
Rent - cost of services98,223 95,107 288,454 283,250 
General and administrative expense138,409 102,528 365,032 301,579 
Depreciation and amortization20,081 14,401 58,279 40,284 
Total Operating Expenses $1,398,857 $1,258,298 $4,017,983 $3,716,045 
Operating income99,721 86,269 329,087 214,908 
Other (Expense) Income
Interest expense(5,099)(8,529)(17,565)(19,787)
Other (expense) income, net(3,308)(1,444)(635)2,517 
Total Other Expense, Net $(8,407)$(9,973)$(18,200)$(17,270)
Income before provision for income taxes91,314 76,296 310,887 197,638 
Provision for income taxes30,502 23,966 93,058 65,962 
Net Income$60,812 $52,330 $217,829 $131,676 
Less:
Net loss attributable to noncontrolling interest(6)(76)(54)(165)
Net Income Attributable To PACS Group, Inc.$60,818 $52,406 $217,883 $131,841 
Net Income Per Share Attributable To PACS Group, Inc.
Basic$0.38 $0.33 $1.38 $0.84 
Diluted$0.37 $0.32 $1.34 $0.80 
Weighted-Average Common Shares Outstanding
Basic158,370,645 156,575,127 157,857,169 156,034,409 
Diluted163,914,936 164,709,367 162,837,785 165,492,441 


6


PACS GROUP, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(dollars in thousands)
The following table presents selected data from our condensed consolidated statements of cash flows for the periods presented:
Nine Months Ended September 30,
20262025
Net cash provided by/(used in):
Operating activities$583,079 $407,614 
Investing activities(538,234)(145,879)
Financing activities(148,703)(63,521)
Net change in cash(103,858)198,214 
Cash, cash equivalents, and restricted cash - beginning of period232,051 160,842 
Cash, cash equivalents, and restricted cash - end of period$128,193 $359,056 


7


PACS GROUP, INC. AND SUBSIDIARIES
UNAUDITED KEY SKILLED SERVICES METRICS


We categorize our facilities into three cohorts. Mature facilities are defined as facilities purchased more than 36 months prior to a respective measurement date. Ramping facilities are defined as facilities purchased within 18 to 36 months prior to a respective measurement date. New facilities are defined as facilities purchased or built less than 18 months prior to a respective measurement date.
The following tables present key skilled services metrics by category for the skilled nursing facilities in each of the three facility cohorts, and for all skilled nursing facilities as of and for the three and nine months ended September 30, 2026 and 2025:
Three Months Ended September 30, 2026
MatureRampingNewTotal
(Dollars in thousands)
Skilled nursing services revenue (1)
$1,000,986 $384,892 $65,443 $1,451,321 
Skilled mix by revenue (2)
53.1 %39.8 %39.5 %48.9 %
Skilled mix by nursing patient days (3)
31.3 %25.7 %21.1 %29.1 %
Occupancy for skilled nursing services:
Available patient days2,018,762 943,742 214,837 3,177,341 
Actual patient days1,880,152 820,849 163,753 2,864,754 
Occupancy rate (operational beds) (4)
93.1 %87.0 %76.2 %90.2 %
Number of facilities at period end196 90 35 321 
Number of operational beds at period end22,402 9,880 3,651 35,933 

Three Months Ended September 30, 2025
MatureRampingNewTotal
(Dollars in thousands)
Skilled nursing services revenue (1)
$746,242 $282,160 $282,531 $1,310,933 
Skilled mix by revenue (2)
55.4 %40.6 %35.6 %48.0 %
Skilled mix by nursing patient days (3)
33.0 %22.0 %23.6 %28.2 %
Occupancy for skilled nursing services:
Available patient days1,481,700 725,220 787,708 2,994,628 
Actual patient days1,404,408 624,612 635,013 2,664,033 
Occupancy rate (operational beds) (4)
94.8 %86.1 %80.6 %89.0 %
Number of facilities at period end149 62 79 290 
Number of operational beds at period end16,406 8,116 8,155 32,677 
Nine Months Ended September 30, 2026
MatureRampingNewTotal
(Dollars in thousands)
Skilled nursing services revenue (1)
$2,748,007 $1,085,770 $372,233 $4,206,010 
Skilled mix by revenue (2)
54.1 %42.6 %40.3 %49.8 %
Skilled mix by nursing patient days (3)
32.0 %26.7 %25.7 %29.8 %
Occupancy for skilled nursing services:
Available patient days5,412,916 2,572,064 1,124,381 9,109,361 
Actual patient days5,079,057 2,257,399 903,360 8,239,816 
Occupancy rate (operational beds) (4)
93.8 %87.8 %80.3 %90.5 %
Number of facilities at period end196 90 35 321 
Number of operational beds at period end22,402 9,880 3,651 35,933 

8


Nine Months Ended September 30, 2025
MatureRampingNewTotal
(Dollars in thousands)
Skilled nursing services revenue (1)
$2,147,833 $807,434 $887,886 $3,843,153 
Skilled mix by revenue (2)
56.4 %41.9 %38.2 %49.1 %
Skilled mix by nursing patient days (3)
33.7 %22.8 %24.7 %28.9 %
Occupancy for skilled nursing services:
Available patient days4,238,699 2,047,146 2,538,192 8,824,037 
Actual patient days4,025,794 1,764,784 2,056,273 7,846,851 
Occupancy rate (operational beds) (4)
95.0 %86.2 %81.0 %88.9 %
Number of facilities at period end149 62 79 290 
Number of operational beds at period end16,406 8,116 8,155 32,677 
__________________
(1)Portion of patient and resident service revenue generated from all patients in skilled nursing facilities.
(2)Portion of routine revenue generated from treating high acuity Medicare and managed care patients.
(3)Number of days that high acuity Medicare and managed care patients receive skilled nursing services at skilled nursing facilities as a percentage of the total number of days that patients from all payor sources receive skilled nursing services at skilled nursing facilities.
(4)Total number of patients occupying a bed in a skilled nursing facility as a percentage of the beds in such facility that are available for occupancy.

9


The following tables present additional detail regarding our skilled mix, including our percentage of revenue and nursing patient days by payor source for the skilled nursing facilities in each of the three facility cohorts, and for all skilled nursing facilities, for the three and nine months ended September 30, 2026 and 2025:

Skilled mix by revenue:
Three Months Ended September 30, 2026
MatureRampingNewTotal
Medicare37.3 %23.7 %21.8 %32.9 %
Managed care15.8 16.1 17.7 16.0 
Skilled mix53.1 39.8 39.5 48.9 
Medicaid36.9 49.6 47.7 40.8 
Private and other10.0 10.6 12.8 10.3 
Total100.0 %100.0 %100.0 %100.0 %
Three Months Ended September 30, 2025
MatureRampingNewTotal
Medicare39.6 %27.8 %18.9 %32.7 %
Managed care15.8 12.8 16.7 15.3 
Skilled mix55.4 40.6 35.6 48.0 
Medicaid35.7 49.9 53.7 42.6 
Private and other8.9 9.5 10.7 9.4 
Total100.0 %100.0 %100.0 %100.0 %
Nine Months Ended September 30, 2026
MatureRampingNewTotal
Medicare38.4 %26.9 %21.7 %33.8 %
Managed care15.7 15.7 18.6 16.0 
Skilled mix54.1 42.6 40.3 49.8 
Medicaid36.5 47.1 48.8 40.4 
Private and other9.4 10.3 10.9 9.8 
Total100.0 %100.0 %100.0 %100.0 %
Nine Months Ended September 30, 2025
MatureRampingNewTotal
Medicare41.0 %30.0 %20.8 %33.9 %
Managed care15.4 11.9 17.4 15.2 
Skilled mix56.4 41.9 38.2 49.1 
Medicaid35.0 48.7 51.9 41.9 
Private and other8.6 9.4 9.9 9.0 
Total100.0 %100.0 %100.0 %100.0 %
10


Skilled mix by nursing patient days:
Three Months Ended September 30, 2026
MatureRampingNewTotal
Medicare19.6 %13.6 %10.6 %17.4 %
Managed care11.7 12.1 10.5 11.7 
Skilled mix31.3 25.7 21.1 29.1 
Medicaid58.6 62.0 62.9 59.8 
Private and other10.1 12.3 16.0 11.1 
Total100.0 %100.0 %100.0 %100.0 %
Three Months Ended September 30, 2025
MatureRampingNewTotal
Medicare21.0 %12.4 %11.1 %16.6 %
Managed care12.0 9.6 12.5 11.6 
Skilled mix33.0 22.0 23.6 28.2 
Medicaid57.7 67.8 64.2 61.6 
Private and other9.3 10.2 12.2 10.2 
Total100.0 %100.0 %100.0 %100.0 %
Nine Months Ended September 30, 2026
MatureRampingNewTotal
Medicare20.3 %14.7 %12.2 %17.9 %
Managed care11.7 12.0 13.5 11.9 
Skilled mix32.0 26.7 25.7 29.8 
Medicaid58.3 61.6 61.0 59.5 
Private and other9.7 11.7 13.3 10.7 
Total100.0 %100.0 %100.0 %100.0 %
Nine Months Ended September 30, 2025
MatureRampingNewTotal
Medicare21.8 %13.9 %11.6 %17.4 %
Managed care11.9 8.9 13.1 11.5 
Skilled mix33.7 22.8 24.7 28.9 
Medicaid57.1 67.1 64.0 61.2 
Private and other9.2 10.1 11.3 9.9 
Total100.0 %100.0 %100.0 %100.0 %

11


The following tables present average daily rates by payor source, excluding services that are not covered by the daily rate, for the three and nine months ended September 30, 2026 and 2025:
Three Months Ended September 30, 2026
MatureRampingNewTotal
Medicare$990.62 $826.68 $761.64 $945.96 
Managed care704.32 627.71 623.52 677.41 
Total for skilled patient payors (1)
883.93 732.60 692.74 837.66 
Medicaid327.89 378.66 280.32 340.12 
Private and other514.40 411.95 296.06 464.04 
Total (2)
$520.70 $473.81 $369.75 $498.64 
Three Months Ended September 30, 2025
MatureRampingNewTotal
Medicare$988.41 $991.53 $746.97 $950.49 
Managed care686.21 595.45 586.21 642.83 
Total for skilled patient payors (1)
878.36 819.35 661.91 824.34 
Medicaid324.26 326.92 366.42 335.43 
Private and other495.26 418.77 385.54 446.20 
Total (2)
$523.14 $444.63 $438.53 $484.57 
Nine Months Ended September 30, 2026
MatureRampingNewTotal
Medicare$997.23 $881.85 $743.96 $952.31 
Managed care710.83 629.87 574.16 671.65 
Total for skilled patient payors (1)
892.67 768.56 654.68 839.77 
Medicaid329.84 368.72 334.18 341.36 
Private and other512.31 425.35 341.84 462.71 
Total (2)
$527.48 $482.17 $417.55 $503.02 
Nine Months Ended September 30, 2025
MatureRampingNewTotal
Medicare$984.00 $981.22 $773.80 $946.64 
Managed care682.71 604.84 577.61 637.92 
Total for skilled patient payors (1)
877.92 833.92 670.02 823.56 
Medicaid322.18 330.12 350.65 331.95 
Private and other492.48 425.86 380.83 443.96 
Total (2)
$525.23 $454.83 $432.96 $485.22 
__________________
(1)Represents weighted average of revenue generated by Medicare and managed care payor sources.
(2)Represents weighted average.

12


The following tables present the above key skilled services metrics by category for all skilled nursing facilities in operation on January 1, 2025, excluding divestitures since that time, as of and for the three and nine months ended September 30, 2026 and 2025:
Three Months Ended September 30,
20262025ChangeChange %
Total Same-Store Facility Results(Dollars in thousands)
Skilled nursing services revenue$1,378,842 $1,295,757 $83,085 6.4 %
Skilled mix by revenue49.1 %48.1 %100 bps2.1 %
Skilled mix by nursing patient days29.5 %28.3 %120 bps4.2 %
Occupancy for skilled nursing services:
Actual patient days2,690,014 2,625,289 64,725 2.5 %
Occupancy rate (operational beds)91.3 %89.3 %200 bps2.2 %
Number of facilities at period end284 284 — — %
Nine Months Ended September 30,
20262025ChangeChange %
Total Same-Store Facility Results(Dollars in thousands)
Skilled nursing services revenue$4,073,750 $3,817,198 $256,552 6.7 %
Skilled mix by revenue49.7 %49.3 %40 bps0.8 %
Skilled mix by nursing patient days29.8 %29.0 %80 bps2.8 %
Occupancy for skilled nursing services:
Actual patient days7,947,669 7,775,749 171,920 2.2 %
Occupancy rate (operational beds)90.9 %89.3 %160 bps1.8 %
Number of facilities at period end284 284 — — %
13


PACS GROUP, INC. AND SUBSIDIARIES
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(dollars in thousands except share and per share data)
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
(in thousands except share and per share data)
Net income$60,812 $52,330 $217,829 $131,676 
Less: Net loss attributable to noncontrolling interest(6)(76)(54)(165)
Net income attributable to PACS Group, Inc.$60,818 $52,406 $217,883 $131,841 
Adjustments:
Acquisition related costs4,350 101 5,084 310 
Stock-based compensation expense45,320 12,516 91,500 38,322 
Legal and other costs9,496 19,596 29,440 66,460 
Provision for income taxes on non-GAAP adjustments (1)
(15,975)(8,697)(34,026)(28,375)
Adjusted Net Income$104,009 $75,922 $309,881 $208,558 
Weighted-average diluted common shares outstanding163,914,936 164,709,367 162,837,785 165,492,441 
Diluted earnings per share$0.37 $0.32 $1.34 $0.80 
Adjusted Earnings Per Share$0.63 $0.46 $1.90 $1.26 
__________________
(1)Represents the Company’s combined federal and state statutory tax rate of approximately 27% for the three and nine months ended September 30, 2026 and 2025.
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net income$60,812 $52,330 $217,829 $131,676 
Less: Net loss attributable to noncontrolling interest(6)(76)(54)(165)
Net income attributable to PACS Group, Inc.$60,818 $52,406 $217,883 $131,841 
Add: Interest expense5,099 8,529 17,565 19,787 
Provision for income taxes30,502 23,966 93,058 65,962 
Depreciation and amortization20,081 14,401 58,279 40,284 
EBITDA$116,500 $99,302 $386,785 $257,874 
Adjustments to EBITDA:
Acquisition related costs4,350 101 5,084 310 
Stock-based compensation expense45,320 12,516 91,500 38,322 
Legal and other costs9,496 19,596 29,440 66,460 
Adjusted EBITDA$175,666 $131,515 $512,809 $362,966 
Rent - cost of services98,223 95,107 288,454 283,250 
Adjusted EBITDAR$273,889 $801,263 
Additional information
Non-cash rent expense (1)
$10,118 $11,931 $31,330 $37,071 
__________________
(1)Non-cash rent expense reflects the extent to which our GAAP rent expense recognized exceeded (or was less than) our cash rent payments.
Non-GAAP Financial Measures
In addition to our results provided throughout that are determined in accordance with GAAP, we also present the following non-GAAP financial measures: Adjusted Net Income, Adjusted Earnings Per Share, EBITDA, Adjusted EBITDA and Adjusted EBITDAR (collectively, Non-GAAP Financial Measures). Adjusted Net Income, Adjusted Earnings Per Share, EBITDA and Adjusted EBITDA are performance measures. Adjusted EBITDAR is a valuation measure. These Non-GAAP Financial Measures have no standardized meaning defined by GAAP, and therefore have limitations as analytical tools, and they should not be considered in isolation, or as a substitute for analysis of our results as reported in accordance with GAAP. You should review the reconciliation of net income to the Non-GAAP Financial Measures in the table above, together with our current quarter condensed consolidated financial statements and the related notes in their entirety, and
14


should not rely on any single financial measure. Additionally, other companies may define these or similar Non-GAAP Financial Measures with the same or similar names differently, and because these Non-GAAP Financial Measures are not standardized, it may not be possible to compare these financial measures to those of other companies. A reconciliation of Adjusted EBITDA guidance to Net Income on a forward-looking basis cannot be provided without unreasonable efforts, as the Company is unable to provide reconciling information with respect to provision for income taxes, interest expense, depreciation and amortization, and certain other expenses that are not representative of our underlying operating performances, all of which are adjustments to Adjusted EBITDA.

Performance Measures
We use Adjusted Net Income, Adjusted Earnings Per Share, EBITDA, and Adjusted EBITDA to facilitate internal comparisons of our historical operating performance on a more consistent basis, as well as for business planning and forecasting purposes. In addition, we believe the presentation of these measures is useful to investors, analysts and other interested parties in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our ongoing operating performance.
Adjusted Net Income – We calculate Adjusted Net Income as net income, adjusted for net loss attributable to noncontrolling interest, further adjusted for non-core business items as listed in Adjusted EBITDA, as well as the related income tax effects of these adjustments.
Adjusted Earnings Per Share – We calculate Adjusted Earnings Per Share by dividing Adjusted Net Income by the weighted‑average diluted shares outstanding for the applicable period.
EBITDA – We calculate EBITDA as net income, adjusted for net loss attributable to noncontrolling interest, before: interest expense; provision for income taxes; and depreciation and amortization.
Adjusted EBITDA – We calculate Adjusted EBITDA as EBITDA further adjusted for non-core business items, which for the reported periods includes, to the extent applicable, costs incurred to acquire operations that are not capitalizable, stock-based compensation expense, legal and other costs, and certain one-time expenses that are not representative of our underlying operating performance. Costs related to acquisitions include costs related to our acquisition of operations, including related costs such as legal fees, financial and tax due diligence, consulting and escrow fees. Legal and other costs include legal and professional fees incurred associated with the Audit Committee’s independent investigation during the years ended December 31, 2025 and 2024, and with other ongoing investigations and SEC matters.
Valuation Measure
We use Adjusted EBITDAR as a measure to determine the value of prospective acquisitions and to assess the enterprise value of our business without regard to differences in capital structures and leasing arrangements. In addition, we believe that Adjusted EBITDAR is also a commonly used measure by investors, analysts and other interested parties to compare the enterprise value of different companies in the healthcare industry without regard to differences in capital structures and leasing arrangements, particularly for companies with operating and finance leases. For example, finance lease expenditures are recorded in depreciation and interest and are therefore removed from Adjusted EBITDA, whereas operating lease expenditures are recorded in rent expense and are therefore retained in Adjusted EBITDA. Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP, and is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring cash operating expense, and is therefore presented only for the current period. While we believe that Adjusted EBITDAR provides useful insight regarding our underlying operations, excluding the impact of our operating leases, we must still incur cash operating expenses related to our operating leases and rent and such expenses are necessary to operate our leased operations. As a result, Adjusted EBITDAR may understate the extent of our cash operating expenses for the respective period relative to our cash needs to operate our leased operations and business.

Adjusted EBITDAR – We calculate Adjusted EBITDAR as Adjusted EBITDA plus rent-cost of services.
15

Filing Exhibits & Attachments

4 documents

Keep reading